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Multiple myeloma (MM) is a lymphoid disease of the elderly with a median age of onset of 65 years, and a median survival of three years. 
Currently, the optimal treatment for patients more than 
65 years old is not well defined, in part because these 
patients are underrepresented in clinical studies, and 
this population is very heterogeneous in disease and de-
mographic characteristics. Autologous stem cell trans-
plantation (auto-SCT) after high-dose melphalan che-
BACKGROUND AND OBJECTIVE: the optimal treatment of patients with multiple myeloma (mm) is not well 
defined, in part because these patients are underrepresented in clinical studies. autologous stem cell transplan-
tation (auto-sCt) after high-dose melphalan chemotherapy can result in a prolonged response duration and 
survival in patients under 65 years of age.
DESIGN AND SETTING: single-center, retrospective study of patients treated at Paoli-Calmettes institute Cancer 
Centre, between January 1994 and January 2007 (96 months)
PATIENTS AND METHODS: We compared the outcome of elderly (age >65 years) patients with younger pa-
tients aged between 60 and 65 years with mm. 
RESULTS: We compared 82 elderly patients with 104 younger patients. Except for age, both groups had com-
parable demographic features, disease characteristics, and prognostic factors. induction VaD chemotherapy 
was comparable between the elderly (87%) and younger (94%) group. Prior to auto-sCt, the calculated hema-
topoietic cell transplantation-specific co-morbidity index was also comparable. With a median follow-up of 41 
months (range, 5-227 months) after auto-sCt, 120 patients were still alive. Disease progression (n=40; 61%) 
was the main cause of death, and it was comparable in the two groups. auto-sCt-related mortality was 3.8% 
(n=4/104) in younger and 3.7% (n=3/82) in older patients. Comparing younger/older subjects, progression-free 
survival was significantly higher in the younger group (P<.0001). however, disease response rates after the first 
auto-sCt was comparable and overall survival (os) was also comparable (57% vs. 54% at 5 years, P=ns; 32% 
vs. 24% at 10 years, P=ns). in a Cox multivariate analysis model, none of the relevant characteristics was shown 
to be a critical prognostic feature for os.
CONCLUSIONS: age was insignificant for both os and transplant-related mortality. We conclude that there 
is no biological justification for an age-discriminate policy for mm therapy. Physiologic aging is likely more 
important than chronologic aging.
motherapy can result in a prolonged response duration 
and survival in patients under 65 years.1,2
Since the introduction of auto-SCT for MM, our 
patients were eligible for high-dose therapy up to age 
70.3-5 In recent years, we essentially discontinued an up-
per age limit when disease severity was judged to out-
weigh the anticipated toxicities from HDT, as per the 
recommendation of the French Francophone Myeloma 
Intergroup (IFM).
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Table 1. Baseline characteristics and treatments received prior to auto-SCT.
Characteristic
Total 
population
n=186 (%)
60-65 years 
group
n=104 (%)
>65 years 
group
n=82 (%)
P*
Median age 
(range; years)
64 (60-77) 61.9 (60-65) 68.5 (65.1-77) nA
Male/Female
10 (55) / 
8 (45)
61 (59) /
4 (41)
42 (51) /
40 (49) .1
Myeloma stage at 
diagnosisa
   i 20 (11) 12 (12) 8 (10)
.45   ii 24 (1) 16 (15) 8 (10)
   iii 142 (76) 76 (7) 66 (80)
Monoclonal component
   igg 101 (55) 57 (55) 44 (54)
.97
   igA 47 (25) 27 (26) 20 (24)
   Light chain 6 (19) 19 (18) 17 (21)
   non secretory 1 (0.5) 1 (1) 0
   igd 1 (0.5) 0 1 (1)
Light chain
   Kappa 121 (66) 72 (69) 49 (60)
.16   Lambda 55 (0) 29 (28) 26 (2)
   Other 10 (4)  (4) 7 (8)
Cytogenetic at diagnosis
   normal 164 92 72
.9
   del(1) del (17) t (4;14) 22 12 10
Beta-2 
microglobulinemia
   ≤ 2.5 120 (64) 67 (64) 5 (65) .98
   > 2.5 66 (6) 7 (6) 29 (5)
Induction therapy at 
diagnosis
   VAd 169 (91) 98 (94) 71 (87)
.20   mP  (2) 1 (1) 2 (2)
   Other 14 (7) 5 (5) 9 (11)
Comorbidity score prior 
to auto-SCTb
   0  125 (68) 70 (67) 55 (67)
.20
   1 15 (8) 10 (10) 5 (6)
   2 15 (8) 6 (6) 9 (11)
    21 (11) 10 (10) 11 (1)
   > 7 (4) 5 (4) 2 (2)
   not available  (2)  () 0
aAccording to Salmon and durie classification; bThe comorbidity score index was calculated using Sorror score.
VAd: vincristine, Adriamycin (doxorubicin), dexamethasone; mP: oral melphalan, prednisone.
Values are n (%) or n.
Unfortunately, only a few patients with MM are able 
to receive HDT. However, this therapeutic approach is 
proposed more and more in older patients because of 
improvements in supportive care in the last years, par-
ticularly the use of the granulocyte-colony stimulating 
factor (G-CSF), which has reduced significantly the 
transplant-related mortality (TRM). Moreover many 
studies have shown the efficacy and tolerability of au-
totransplantation in some selected myeloma patients 
more than 65 years old.1,6-8
The realization of an autologous SCT in older pa-
tients presents several challenges in the field of the clini-
cal research. The first of these challenges is related to 
the selection of patients to identify those clearly able 
to profit from this therapeutic strategy and especially 
those who can tolerate the intensive chemotherapy with 
minimal toxicity. Indeed, some factors related to each 
patient, like comorbidities or performance status, or 
factors related directly to the myeloma disease still need 
to be identified. The concept of patient stratification is 
very important to distinguish the concept “of physiolog-
ical age” from that of “the chronological age”. The second 
challenge is related to the best regimen of conditioning 
for auto-SCT and the use of the best intensive chemo-
therapy so as to maximize the efficacy and reduce the 
toxicities in these fragile old patients. 
Recently, TRM has decreased considerably due to 
prompt neutrophil recovery with peripheral blood stem 
cell (PBSC) rescue so this treatment can be considered 
in individuals with myeloma over the age of 65 years.5,9-
12 These patients have previously been excluded from 
high-dose programs purely on the basis of age, but have 
otherwise met all the other prerequisites. Lastly, in el-
derly patients, prophylactic care after intensive chemo-
therapy is an important objective to preserve the quality 
of life of these patients. So the auto-SCT in older my-
eloma patients requires individual consideration taking 
into account of the heterogeneity and the relative co-
morbidities in this special population. 
PATIENTS AND METHODS
This single center retrospective analysis assessed the 
outcome of consecutive MM patients aged over 60 
years, treated with auto-SCT at the Institut Paoli-
Calmettes Cancer Centre, Marseille, France, treated be-
tween January 1994 and January 2007 (96 months)with 
the specific aim to compare the outcome of “elderly” 
(age >65 years) patients, with “younger” patients aged 
between 60 and 65 years treated in the same period and 
in the same auto-SCT program. 
The type of mobilization regimen for PBSC collec-
tion was similar in both groups, with G-CSF alone or 
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Table 2a. Auto-SCT features and transplant-related events.
Characteristic
Total 
population
N=186 (%)
60-65 years 
group
n=104 (%)
>65 years 
group
n=82 (%)
P
Mobilization regimen 
PBSC collection
   g-CSF alone 11 (61) 57 (55) 56 (68)
.20   Chemotherapy and 
   g-CSF 7 (9) 47 (45) 26 (2)
Performance status at 
time of auto-SCT
   0 90 (48) 2 (1) 58 (71)
<.0001
   1 81 (4) 60 (58) 21 (26)
   2 14 (8) 11 (10)  (4)
    1 (1) 1 (1) 0
Disease status at time of 
auto-SCT
   Cr or VgPr 24 (1) 15 (15) 9 (11)
.11
   Pr 119 (64) 64 (61) 55 (67)
   Sd 12 (7)  () 9 (11)
   refractory 21 (11) 1 (12) 8 (10)
   not evaluable 10 (5) 9 (9) 1 (1)
Auto-SCT conditioning 
regimen (mg/m2)
   melphalan 100 15 (8) 0 15 (18)
<.0001
   melphalan 140 11 (61) 56 (54) 57 (70)
   melphalan 200 5 (28) 45 (4) 8 (10)
   Other 5 ()  () 2 (2)
Time (days) to ANC>500/
µL (median, range)a
1 (6-25) 1 (6-25) 14 (8-22) .25
Time (days) to 
platelets>20000/µL 
(median, range)b
15 (8-2) 14.5 (8-2) 15 (9-26) .049
Total length (days) of 
hospitalization during 
auto-SCT (median; 
range)
18 (2-9) 19 (2-2) 17 (2-9) .18
Mucositisc
   grade 0-1 40 (29) 14 (20) 26 (42)
.09   grade 2 5 (8) 28 (40) 25 (7)
   grade -4 45 () 28 (40) 17 (25)
with chemotherapy; the performance status at time of 
auto SCT, and the disease status at the time of auto 
SCT was similar also. Before being admitted for high-
dose melphalan and autologous SCT, all patients were 
screened for the absence of cardiac failure (checkup 
included echocardiography with a required a forced 
expiratory volume > 50%, or an absence of respiratory 
failure; diffusing capacity for carbon monoxide > 50%), 
and renal or hepatic failure (biological parameters). 
Patient characteristics were matched for the main risk 
factors previously identified to affect event-free sur-
vival and overall survival (OS) after autotransplants.10,11 
Hematopoietic cell transplantation-specific co-mor-
bidity index (adapted from the Charlson Comorbidity 
Index” was calculated for each patient.
All data were computed using SPSS for Windows 
(SPSS Inc., Chicago, IL) and SEM software (SILEX, 
Mirefleurs, France). The Mann–Whitney test was used 
for comparison of continuous variables. Categorical 
variables were compared using the chi-square test, the 
cumulative incidence method as previously described. 
Cumulative incidence estimates were also used to mea-
sure the probability of relapse or progression.13 OS 
was calculated from the date of the first auto SCT to 
death from any cause. Progression-free survival (PFS) 
was calculated from the date of the first auto-SCT to 
disease progression, disease relapse, or patient death. 
PFS and OS were estimated from the time of the first 
auto-SCT using the Kaplan-Meier product-limit esti-
mates. Differences between groups were tested using 
the log-rank test.14
RESULTS
This single-center retrospective analysis evaluated the 
results of 186 consecutive patients with MM treated by 
auto-SCT over a period of 96 months. We compared 
the results of 82 “old patients” (age> 65 years) who were 
matched with 104 “young patients” (age between 60 
and 65 years) treated during the same time and with 
the same program of auto-SCT. The median age in our 
total population of 186 patients was 64 years (range, 
60-77 years). The median age in the younger group was 
61.9 years and in the older group was 68.5 years (Table 
1). Except for age, the two groups were comparable (dif-
ferences statistically nonsignificant) in demographic 
and disease (the stage of the disease, monoclonal 
components) characteristics and in prognostic factors 
(bêta2-microglobulin). The distribution of sex in the 
two groups was not significantly different. There was 
no difference between the groups in the myeloma stage 
at diagnosis, the type of monoclonal component pro-
tein, the light chain type, the rate of beta-2 microglob-
adata available for 169 patients; bdata available for 140 patients; cdata available for 18 patients.
Abbreviations: AnC: absolute neutrophil count; auto-SCT, one or more autologous stem cell transplantations; Cr, 
complete remission; Pr, partial remission; VgPr, very good partial response; Pd, progressive disease; Sd, stable 
disease.
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Characteristics
Total 
population 
N=186 (%)
60-65 years 
group
n=104 (%)
>65 years 
group
n=82 (%)
P
Documented infectionsa
   Bacteria 4 (18) 18 (17) 16 (20)
.10
   Fungal 8 (4) 7 (7) 1 (1)
   interstitial pneumonia 10 (6) 8 (8) 2 ()
   none 14 (72) 71 (68) 6 (77)
Other serious or 
life-threatening 
complications
19 (10) 12 (12) 7 (9) .50
Patients transferred to 
the ICU
12 (7) 6 (6) 6 (7) .67
Response after the first 
auto-SCT
   Cr or VgPr 84 (45) 50 (48) 4 (41)
.58
   Pr 82 (44) 42 (40) 40 (49)
   Sd 1 (1) 1 (1) 0
   Progressive 12 (6) 8 (8) 4 (5)
   not evaluable 7 (4)  () 4 (5)
Cause of death (total 
no.)
66 (5) 40 (8) 26 (2)
.44
   disease 40 (61) 27 (26) 1 (2)
   Transplant-related 
   mortality 7 (11) 4 (4)  (4)
   infections 10 (15) 4 (4) 6 (7)
   Other 9 (14) 5 (5) 4 (5)
Disease status at last 
follow-up
   Cr or VgPr 7 (20) 19 (18) 18 (22)
.86
   Pr 17 (9) 9 (9) 8 (10)
   Sd 6 (19) 22 (21) 14 (17)
   Progressive 92 (50) 51 (49) 41 (50)
   not evaluable 4 (2)  () 1 (1)
anon-microbiologically documented infections were not analyzed. 
Abbreviations: auto-SCT, one or more autologous stem cell transplantations; Cr, complete remission; Pr, partial 
remission; VgPr, very good partial response; Pd, progressive disease; Sd, stable disease.
Table 2b. Auto-SCT features and transplant-related events.ulinemia, the type of induction therapy at diagnosis, 
the comorbidity score prior auto-SCT. Specifically, 
the incidence of favorable cytogenetics (absence of ab-
errations of chromosomes 13 and 17 as well as any 
translocation) was similar in the young patients and 
the older cohorts (Table 1).
 The majority of the patients (91%) received VAD 
homogeneous induction chemotherapy, which was 
comparable between the old patients (87%) and the 
young patients (94%). There were some statistically 
significant differences in melphalan dose as a condi-
tioning regimen; 45 (43%) patients received melpha-
lan at a full dose at 200mg/m2 in the young group 
compared to only 8 (10%) patients in the older group; 
(P<.0001). Before the realization of the auto-SCT, 
the evaluation of the comorbidities with the score of 
Charlson adapted to the SCT was also comparable 
between the two groups (77% of the young patients 
presenting a score 0-1, against 73% in the group of the 
old patients; P=NS).
There were some differences between the two 
groups in performance status at time of auto-SCT 
that were statistically significant; 12 (11%) patients in 
the young group vs 3 (4%) patients in the older group 
had a PS grade 2-3; (P<.0001) (Table 2a). Thirty-
three percent of the young patients and 28% of the old 
patients (P=NS) received a second auto-SCT.
The most common adverse reactions to stem cell 
infusion were nausea and vomiting; hypertension or 
tachycardia and they were not different between the 
two groups. There was no difference in longer post-
transplant hospital stay for the elderly group in me-
dian (17 days) or range (2-39) compared with the 
younger group (19 days) or range (2-32); (P=0.18) 
The proportion of patients attaining WBC engraft-
ment (as indicated by an absolute neutrophil count 
(ANC) >500 for three consecutive days) was similar 
in both groups, (P=0.25) (Table 2a). Similarly, the 
proportion of patients achieving a platelet count over 
20 000 was similar for both groups. The most com-
mon post-transplant toxicities that were encountered 
included nausea, mucositis, diarrhea and neutropenic 
fever. Post-transplant mucositis was not different in 
the two groups, but important mucositis (grade 3-4) 
was statistically significantly greater in the younger 
group (P=.039) probably because of the lower doses 
of melphalan received in the older group. The inci-
dence of post-transplant bacteremias, fungal and in-
terstitial pneumonia was similar in the two groups 
(Table 2b). There was no difference also in other seri-
ous life-threatening complications, the number of pa-
tients transferred in the ICU, or in the number who 
died of transplant-related causes. 
One hundred twenty patients were still alive af-
ter autoSCT, with a median follow-up of 41 months 
(range, 5-227 months). Disease progression (n=40; 
61%) was the main cause of the death, at a compa-
rable rate in the two groups (Table 2b). PFS after the 
first auto SCT was significantly higher in the young 
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patients (37% vs 22% at 5 years) (P<.0001) (Figure 
1). The median PFS was 45 months in the younger pa-
tients vs 27 months in the older patients, probably be-
cause the older patients had more frequently received 
melphalan 140 mg/m² instead 200mg/m². However, 
the remission rate after the first auto-SCT was com-
parable (the rate of CR, VGPR and PR: 88% against 
90%, P=NS) and the overall survival (OS) were also 
comparable (57% vs 54% at 5 years, P=NS and 32% vs 
24% at 10 years, P=NS) (Figure 2). 
The TRM as cause of death was compared in the 
two groups (Table 2b). Disease status at the last fol-
low up was also comparable: CR or VGPR+PR and 
disease progression at the last follow up was compa-
rable. In a multivariate analysis, none of the analyzed 
characteristics (age, melphalon dose, disease status of 
the transplant) had a significant impact on the overall 
survival. Also we did not find an influence of age on 
survival nor on TRM. 
DISCUSSION 
We have demonstrated a similar outcome for patients 
older than 65 years and for patients in the 60-65 year 
old population. This matched analysis allows for a better 
estimate of the outcome of these patients, by eliminat-
ing the effect of different prognostic factors that could 
often be biased in single group retrospective studies.15,16 
We did not observe any significant differences in the 
response rates or in the time-to-progression following 
transplant between the two groups. We also observed 
that high-dose melphalan with auto-SCT is feasible 
and effective in old patients with MM. The results ob-
tained plead in favor of an equivalent benefit in terms 
of survival in old patients more than 65 years of age, 
without an increased risk of toxicity or mortality.17,18 
In our analysis, the evaluation of comorbidities with 
the score of Charlson adapted to transplanted patients 
showed that the group of young patients is comparable 
with the group old patients.19-21 This is important data, 
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Figure 1. Progression-free survival for all patients (A) and for young (age 60-65 years, n=104) and older patients (age >65 years, n=82).
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Figure 2. Overall survival for all patients (A) and for young (age 60-65 years, n=104) and older patients (age >65 years, n=82).
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which pleads in favor of a precise selection of these pa-
tients because it is allowed because it is commonly be-
lieved that older patients have more comorbidities.22,23 
However, the evaluation of comorbidities cannot reflect 
perfectly or adequately these characteristics in connec-
tion with “the physiological reserves” in older patients. 
Indeed, the personal clinical and functional onco-geri-
atric status of patients can be very variable in spite of 
similar age and comparable comorbidities.24 Beyond the 
development of method for a better selection of the pa-
tients, it appears important, in the context of intensive 
chemotherapies with auto-SCT in older myeloma pa-
tients, to consider the development of a chemotherapy 
approach specifically adapted to age.25-27 
Indeed, the ideal posology for melphalan as the best 
conditioning regimen to auto-SCT was largely defined 
in some studies, but with sometimes contradictory re-
sults.1,15,16 Moreover, it is important to note that within 
the framework of our study, the oldest patients more 
frequently received melphalan at 140 mg/m² instead of 
200 mg/m², which supported certainly the reduction of 
various toxicities. Also in the elderly group, 15 patients 
(18 %) received 100 mg/m² and 8 of those patients un-
derwent a second auto-SCT as part of planned tandem 
transplant (Table 2a).
In addition, the availability of new anti-myeloma 
agents much more specific and less toxic properties (le-
nalidomide and bortezomib), should allow for the de-
velopment of more modern approaches for conditioning 
and less toxicity, including for example, a less important 
role (a lower dose) of melphalan in combination with 
one or more of these drugs.28
The natural history of multiple myeloma is in a 
phase of important change. Major therapeutic progress 
in the last 5 years has made it possible to transform this 
pathology almost into a chronic disease that evolves 
over several years with patients receiving a multitude of 
therapeutic lines with alternation of phases of relapse 
and remission. The availability of these more targeted 
and probably less toxic approaches than auto-SCT 
should however hide the potential benefit of autotrans-
plantation in these patients. New approaches are neces-
sary to evaluate the place of auto-SCT in combination 
with other modern treatments in all patients with MM, 
including the oldest patients. 
Thalidomide, bortezomib, and lenalidomide have 
been combined with corticosteroids, alkylators, and an-
thracyclines in front-line MM treatment. 
Until recently, high rates of CR and other major re-
sponses were primarily seen with autologous SCT in 
young patients, but insights into the biology of MM have 
led to the development and approval of new drugs with 
significant activity, and new induction regimens based 
on these novel agents are offering improved responses. 
The substantial activity seen with these new drug com-
binations has prompted a re-examination of the role of 
autologous SCT in MM treatment. Will achievement of 
major responses with these new regimens translate into 
improved survival after consolidation with transplanta-
tion? Will these improved induction regimens reduce 
the need for tandem transplantation, or does achieve-
ment of CR obviate the need for front-line transplanta-
tion altogether? Is there still a role for autologous SCT 
in elderly MM patients in the era of novel drug? To help 
address these questions, randomized trials are needed, 
as well as tests with improved sensitivity to better de-
fine depth of remission. 26 Beyond the objectives of sur-
vival and toxicity, it appears increasingly important to 
incorporate in clinical research protocols the secondary 
objectives as the measurement of the quality of life or 
the functional status of the patient which should bring 
additional arguments in favor of one or the other of the 
therapeutic sequences.
This report confirms our previous experience that 
age per se does not affect outcome after autotransplant 
for MM, whether examined as a continuous or categori-
cal variable. This finding may be due, in large part, to 
the availability of adequate quantities of CD34+ cells 
in young and old patients, assuring comparable dura-
tions of neutropenia and thrombocytopenia and, thus, 
minimizing the risk of infection and other toxicities. 
Accumulative injury from a second HDT cycle to either 
the bone marrow micro-environment or other critical 
organs was not apparent in either age group. On the 
basis of our data we conclude that optimal therapy for 
MM with PBSC-supported high-dose melphalan ther-
apy should not be withheld from the majority of older 
patients presenting with MM who deserves optimal 
control of their disease and, thereby, gaining hopefully 
many years of high-quality life.
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